Blocknomi
Key Takeaways Guggenheim maintained its Buy recommendation on Abivax (NASDAQ:ABVX) with a $175 price objective following analysis of 44-week maintenance trial data for obefazimod. Shares currently trade at $96.15, representing…
Related articles
-
Kentucky Attorney General Targets Prediction Markets in New Lawsuits
BeInCrypto Published 18.06.2026 12:09
-
ON Semiconductor (ON) Stock Plunges 14% on $7B Synaptics Acquisition Announcement
Blocknomi Published 26.06.2026 12:57
-
Brazil Sees $318B In Crypto Inflows As On-Chain Money Laundering Matures
Bitcoinist Published 20.06.2026 15:00
-
Binance EU Operations at Risk as Greek Regulator May Deny MiCA Compliance License
Blocknomi Published 17.06.2026 08:33
-
BitGo Singapore and dtcpay Join Forces to Scale Digital Asset Payment Solutions
Blocknomi Published 17.06.2026 11:54
-
Ripple CEO Brad Garlinghouse Slams Michael Saylor’s Bitcoin Strategy, Says STRC Is Hurting the Crypto Market
Brave New Coin Published 28.06.2026 04:20
-
Morning Minute: Coinbase Pushes to Become 'Everything Exchange' With Stocks, Perps, and AI
Decrypt Published 17.06.2026 12:18
-
El Salvador Adds to Bitcoin Reserve Again as Daily Buys Push Stack Past 7,680 BTC
Bitcoin.com Published 19.06.2026 09:30